Does NTRA pay a dividend and is it safe?

Natera Inc. (NTRA) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / NTRA / dividends

HUM (64) CI (53) ELV (70) ILMN (70) ⌘ Pro Terminal →

Natera Inc. (NTRA) Dividend Safety Gauge & 10-Year DRIP Compounder

$378.92 -8.54% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $372.38

Natera Inc. (NTRA) carries a Roarable Rating of C+ (Hold) with 68/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C+ • HOLD / WATCH Cap $59.72B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NTRA Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is NTRA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Natera Inc. (NASDAQ: NTRA) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 68/100 at a spot price of $378.92 (-8.54% 1D, market cap $59.72B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 17/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 10/20. Across 1015 tracked Health Care issuers, NTRA ranks #88 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does NTRA compare to HUM and CI in the Health Care sector?

▼

Within the Health Care sector (Medical Specialities), NTRA carries a Roarable C+ (68/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -4.9%. By comparison, HUM (Humana Inc.) holds a C grade (64/100 RQD, P/E 42.2x, ROIC 8.3%, cap $49.77B) and CI (The Cigna Group) posts a D+ grade (53/100 RQD, P/E 13.2x, ROIC 8.8%, cap $78.80B). Among the 5-stock peer group, CI leads on earnings multiple (13.2x) while ILMN leads on capital efficiency (18.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NTRA?

▼

Per NTRA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001604821), Natera Inc. generated $2.31B in revenue (+35.9% YoY), -$208.2M in net income, and $109.1M in free cash flow against $2.40B in total assets and $308.7M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $372.36 (-1.73%)🧬 Disciplined Float (+0.52% YoY Shares)⚙️ Cash Engine: 13/20 (C) • 4.7% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 68/100 (C+) historically posted market-perform odds over rolling 90-day windows (+1.8% avg 90D alpha vs SPY • 56.9% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C+ · Rk B-

Each axis scored 0–20

12M PRICE TARGET CONE+4.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NTRA)Realized 20D OHLCV Swing Band: ±9%

Deterministic 5-Pillar Attribution (68/100 Composite)

🔍 WHY NTRA SCORES 68/100 (C+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+17/20 pts (25% of score)

20D Institutional Volume Accumulation (±9% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (24% of score)

Altman Z-Score 26.00 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution10/20 pts (-10 pt drag)

Disciplined Float (+0.52% YoY Shares) & executive Form 4 sales trim 10 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B+$394.75+4.7% Next Q

Q2 (-2Q)

Grade B$413.38+2.7% Next Q

Q3 (-1Q)

Grade B$424.42-10.7% Next Q

Current

Grade C+$378.92+1.8% Hist 90D α

Trajectory: B+ (76) → C+ (68)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the NTRA Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 68/100 (C+) score, NTRA faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (+0.52% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($382.86) or 200D SMA ($269.04) invalidates the momentum regime and cuts Target Base ($395.97) toward Bear Floor ($308.86).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NTRA• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “NTRA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 68%NO 32%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (15.1% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $40,809

Est. Year-10 Shareholder Yield: $245/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$11.5K

Yr 1

$13.2K

Yr 2

$15.2K

Yr 3

$17.6K

Yr 4

$20.2K

Yr 5

$23.3K

Yr 6

$26.8K

Yr 7

$30.8K

Yr 8

$35.5K

Yr 9

$40.8K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Cash-Flow & Quality Compounder Desk

Cash-Fortress Compounders: Auditing Free Cash Flow & Yield Safety in NTRA & A-Rated Leaders

✓12-month Bull/Base/Bear fair-value walkthrough on NTRA and its top sector peer
✓Top Roarable A-Rated cash compounders with verified executive & 13F accumulation
✓Includes nightly RQD rating-change & forensic signal email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

NTRA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +79.11%▲ ASCENDING CHANNEL

2026-11-03O $436.0H $436.0L $378.9C $378.9VOL 2.43M

RES: $485.7SUP: $335.3SMA50: $382.9SMA200: $269.0

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NTRA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NTRA Butterfly Map → + Track NTRA →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

11.2%/yr Implied 5Y Growth

vs. +35.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on NTRA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NTRA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for NTRA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NTRA)

Health Care Rank #88 of 1015 ⚔️ HUM vs NTRA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NTRA vs. HUM, CI, ELV, ILMN)

Industry: Medical Specialities (41 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Natera Inc. (NTRA) ranks #88 by composite RQD confidence (68/100, grade C+) and #32 by equity capitalization ($59.72B). Within this direct 5-issuer industry benchmark cohort, CI leads on earnings valuation at 13.2x trailing P/E, while ILMN leads on capital efficiency and profitability with 18.2% ROIC and 66.1% gross margin. ELV currently holds the highest overall quantitative score in the immediate peer group at 70/100 (B-) compared with NTRA at 68/100 (C+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
NTRA ACTIVE Natera Inc.	C+	68/100	—	—	-4.9%	-8.54%	$59.72B	Benchmark Subject
HUM Humana Inc.	C	64/100	42.2x	—	8.3%	-0.99%	$49.77B	/hum-vs-ntra →
CI The Cigna Group	D+	53/100	13.2x	21.8%	8.8%	-1.02%	$78.80B	/ci-vs-ntra →
ELV Elevance Health Inc.	B-	70/100	16.1x	89.4%	8.7%	-1.54%	$90.76B	/elv-vs-ntra →
ILMN Illumina Inc.	B-	70/100	51.5x	66.1%	18.2%	-3.99%	$35.63B	/ilmn-vs-ntra →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001604821 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Natera Inc. (NTRA) reported GAAP revenue of $2.31B (+35.9% vs. FY2024 revenue of $1.70B , and +113.0% cumulative change since FY2023) , GAAP net income of -$208.2M, operating cash flow of $215.3M, and free cash flow of $109.1M (+57.6% YoY). On the balance sheet, NTRA closed FY2025 with $2.40B in total assets against $308.7M in total debt (Altman Z-Score: 26.00, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$2.31B	-$208.2M	$215.3M	$109.1M	$2.40B	$308.7M
FY2024 (FY)	2024-12-31	$1.70B	-$190.4M	$135.7M	$69.2M	$1.66B	$209.4M
FY2023 (FY)	2023-12-31	$1.08B	-$434.8M	-$247.0M	-$295.7M	$34.57B	$8.09B

3. NTRA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NTRA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does NTRA compare to HUM and CI in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for NTRA?

Where is NTRA trading relative to its 50-day, 200-day, and 52-week technical levels?

NTRA last traded at $378.92 (-8.54% on volume of 2,627,910 shares), positioning the stock -1.03% below its 50-day simple moving average ($382.86) and +40.84% above its 200-day simple moving average ($269.04). Across its 52-week range of $181.00 to $437.41, NTRA sits at the 77.2% percentile with a 14-day RSI of 53.7 (NEUTRAL RANGE) and an implied next-earnings move of ±9.0% ($344.82 to $413.02).

Direct Sub-Reports: NTRA RQD Cockpit NTRA 12M Forecast NTRA Earnings & Move NTRA Dividends & DRIP NTRA Insiders & 13F NTRA Whale Options NTRA Profit Sankey NTRA News & Why

ROARABLE RATING BRIEF • RQD 68/100 (C+) ✓ SEC XBRL & RQD VERIFIED

NTRA — Natera Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Natera Inc. (NTRA) earns a live Roarable RQD composite score of 68/100, corresponding to a C+ letter grade (Roarable Hold) at a spot price of $378.92 (-8.54% 1D, market capitalization $59.72B).

Fundamental Cash Engine (13/20): Anchored by return on invested capital (ROIC) of -4.9%, gross margin of —, operating margin of -13.4%, and free cash flow yield of 0.17%.
Whale 13F & Options Flow (17/20) + Insider Conviction (10/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (12/20) + Forensic Balance Sheet (16/20): Incorporates a 1.09x equity beta, Altman Z-Score of 26.00, Piotroski F-Score of 7/9, and Debt/Equity of 0.17x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Natera Inc. Is a NASDAQ-listed company in the Health Care sector, Medical Specialities industry. The financials show revenue of $2.31B for FY 2025, indicating a meaningful commercial operation, but the source does not explain the sources of that revenue.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Natera Inc. (NTRA) reported $2.31B in annual revenue (up from $1.70B in FY2024, +35.9% YoY) and -$208.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($1.08B revenue, -$434.8M net income) through FY2025, NTRA scaled operating cash flow to $215.3M and free cash flow to $109.1M, backed by $2.40B in total assets against $308.7M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (C+ • RQD 68/100): Big institutional funds and options desks are actively positioning on the bullish side. Clean SEC annual filing review with no major hidden accounting time-bombs. With Fundamental Cash Engine at 13/20 and Institutional Whale Flow at 17/20, sustained execution supports upside toward the upper end of the $181.00 – $437.41 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -13.4% operating margins and a 1.09x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are therefore — Investors should note that the absence of mapped links means this dossier cannot identify ripple effects from suppliers or customers.

Key Question #1: Can NTRA sustain or expand its -13.4% operating margin and -4.9% ROIC against Medical Specialities peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $2.31B and free cash flow of $109.1M, how will capital allocation balance growth reinvestment against $308.7M in total debt?
Key Question #3: How sensitive is NTRA's 18.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.09x)?

NTRA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Natera Inc. (NTRA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to NTRA Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 1d ago

Natera (NTRA) Stock May Be 33% Below Fair Value Despite FDA Breakthrough News

Yahoo Finance report covering Natera Inc. (NTRA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingKey • 1d ago

Natera Inc Stock (NTRA) Moved Down by 5.30% on Oct 6: A Full Analysis

TradingKey report covering Natera Inc. (NTRA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com • 1d ago

Why is Natera stock sliding today?

Investing.com report covering Natera Inc. (NTRA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 1d ago

Natera: Priced To Perfection Amidst Rising Competitive Threats (NASDAQ:NTRA)

Seeking Alpha report covering Natera Inc. (NTRA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST TradingView • 1d ago

Natera, Inc. Stock 12‑Month Price Target Raised to $387.52, Implies 3% Downside

TradingView report covering Natera Inc. (NTRA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE StockInvest.us • 1d ago

Natera Stock Price Forecast. Should You Buy NTRA?

StockInvest.us report covering Natera Inc. (NTRA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance UK • 1d ago

Natera, Inc. (NTRA) stock price, news, quote and history

Yahoo Finance UK report covering Natera Inc. (NTRA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investor's Business Daily • 1d ago

The Stock Of The Day, And Its Rivals, Are Taking A Breather

Investor's Business Daily report covering Natera Inc. (NTRA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NTRA Bull vs. Bear Conversation Board — What's Your Call at $378.92?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NTRA 🐻 33% BEARISH CONVICTION

MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH 🎯 Target: $484.73 (+17.0%)

📌 Pinned Debate

Strong institutional accumulation (whale 13F flow 19/20) and a forensic balance sheet scoring 16/20 with Debt/Equity of 0.17 and debt r

The street is overcomplicating Natera Inc. (NTRA). Strong institutional accumulation (whale 13F flow 19/20) and a forensic balance sheet scoring 16/20 with Debt/Equity of 0.17 and debt reduced from $8.09B to $308.7M.. With an RQD score of 68/100 (C+) and Forensic Balance Sheet at 16/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $447.44.

SectorRotator 🐂 BULL

@MidwestValue Agree on the RQD 68/100 quality, though with 1.09 beta I'm scaling in with half-size at $414.30 and keeping dry powder in case we test $385.30.

RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH 🎯 Target: $327.30 (-21.0%)

Spot @ $414.30

Negative trailing EPS of -1.44 and ROIC of -4.9% mean the stock trades at $436 without earnings support, with the fundamental cash engi

Negative trailing EPS of -1.44 and ROIC of -4.9% mean the stock trades at $436 without earnings support, with the fundamental cash engine scoring only 13/20.. Look at the math on NTRA: paying 18.0x forward P/E for -4.9% ROIC and -13.4% operating margins leaves zero margin of safety if Medical Specialities demand softens. I'd wait for a retest of $364.58 before getting long.